Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

• Autores principales: Xia Luo (Autor), Qiao Liu (Autor), Zhen Zhou (Autor), Lidan Yi (Autor), Liubao Peng (Autor), Xiaomin Wan (Autor), Xiaohui Zeng (Autor), Chongqing Tan (Autor), Sini Li (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appropriate for widespread use among Chinese advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) patients, our current study was designed to evaluate the cost-effectiveness of first-line...